[1] HUANG K J, SU I J, THERON M, et al. An interferon-γ-related cytokine storm in SARS patients[J]. J Med Virol, 2005, 75(2): 185-194.
[2] HUANG C, WANG Y, WANG X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China [J]. Lancet, 2020,DOI: 10.1016/S0140-6736(20)30183-5.
[3] JENNIFER R T, MARCUS J K,CAMERON P S, et al. Into the eye of the cytokine storm [J]. Microbiol Mol Biol Rev, 2012, 76(1):16-32.
[4] ZHANG H Y,XIE X,ZHANG K J, et al. Effects of cytokine storm on influenza virus infection and its prevention and treatment [J]. Chin J Cell Mol Imm(细胞与分子免疫学杂志),2013,29(5):556-559.
[5] ZHANG Y L,JIANG C Y.Cytokine storms: the dominant hand in acute respiratory distress syndrome [J]. Life Sci(生命科学),2015,27(5):554-557.
[6] CHATENOUD L, FERRAN C, REUTER A, et al. Systemic reaction to the anti-T-cell monoclonal antibody OKT3 in relation to serum levels of tumor necrosis factor and interferon-gamma[J]. N Engl J Med, 1989, 320 (21) :1420-1421.
[7] ERRARA J L, ABHYANKAR S, GILLILAND D G.Cytokine storm of graft-versus-host disease:a critical effector role for interleukin-1[J]. Transplant Proc, 1993, 25 (1 Pt 2) :1216-1217.
[8] DE JONG M D, SIMMONS C P, THANH T T, et al. Fatal outcome of human influenza A (H5N1) is associated with high viral load and hypercytokinemia[J]. Nat Med, 2006, 12 (10) :1203-1207.
[9] WANG J F, JIN B, CAO F L. Advances in the study of cytokine release syndrome induced by CAR-T cell therapy[J]. J Chin Pract Diag Ther(中华实用诊断与治疗杂志),2018,32(12):1228-1231.
[10] SHIMABUKURO-VORNHAGEN A, GÖDEL P, SUBLKLEWE M, et al. Cytokine release syndrome [J]. J Immunother Cancer, 2018, 6(1):56.
[11] SHINYA K, GAO Y, CILLONIZ C, et al. Integrated clinical, pathologic, virologic, and transcriptomic analysis of H5N1 influenza virus-induced viral pneumonia in the rhesus macaque[J]. J Virol, 2012, 86(11):6055-6066.
[12] WANG Q, ZHANG T, SU F,et al. Research status of adverse reactions of cytokine release syndrome[J]. Chin J Clin Pharmacol(中国临床药理学杂志), 2018, 34 (7):906-909.
[13] MAUDE S L, BARRETT D, TEACHEY D T, et al.Managing cytokine release syndrome associated with novel T cell-engaging therapies[J]. Cancer, 2014, 20 (2):119-122.
[14] TANAKA T. IL-6 blockade therapy for inflammatory diseases: current perspectives and future directions [J]. Nihon Rinsho Meneki Gakkai Kaishi, 2015, 38 (6): 433-442.
[15] ALVI R M, FRIGAULT M J, FRADLEY M G, et al. Cardiovascular events among adults treated with chimeric antigen receptor T-cells (CAR-T) [J]. J Am Coll Cardiol, 2019, 74 (25): 3099-3108.
[16] GRUPP S A, MAUDE S, APLENC R, et al. T cells engineered with a chimeric antigen receptor (CAR) targeting CD19 (CTL019) produce complete responses and long-term persistence without GVHD in children with relapsed, refractory ALL [J]. Cancer Res, 2014, 74 (20s): PR06.
[17] SUN Y,ZHANG B,CHEN H.Mechanism and clinical treatment of cytokine release syndrome after CAR-T treatment [J]. Chin J Cancer Biother(中国肿瘤生物治疗杂志),2019,26(4):365-373.
[18] RUSSEL C D,MILLAR J E,BAILLIEJ K. Clinical evidence does not support corticosteroid treatment for SARS-CoV-2 lung injury[J].Lancet,2020,DOI:10.1016/S0140-6736(20)30317-2.
[19] ZOU Y, FAN L, XU W, et al. Progress of cytokine release syndrome caused by chimeric antigen receptor t-cell immunotherapy [J]. J Leuk Lymph, 2017, 26 (11): 697-701.
[20] NORELLI M, CAMISA B, BARBIERA G, et al. Monocyte-derived IL-1 and IL-6 are differentially required for cytokine-release syndrome and neurotoxicity due to CAR T cells[J]. Nat Med, 2018, 24 (6):739-748.
[21] GIAVRIDIS T, VANDERSTEGEN S J C, EYQUEM J, et al. CAR-T cell-induced cytokine release syndrome is mediated by macrophages and abated by IL-1 blockade[J]. Nat Med, 2018, 24 (6) :731-738.
[22] STAEDTKE V, BAI R Y, KIM K, et al. Disruption of a self-amplifying catecholamine loop reduces cytokine release syndrome[J]. Nature, 2018, 564 (7735):273-277.
[23] TAO G F, ZHANG S S, ZHU L Y, et al. Pharmacological mechanism and clinical application of ulinastatin [J]. J China Pharm(中国药房),2017,28(35):5020-5023.
[24] FU Q. Comparison of the anti-inflammatory effects of ulinastatin and glucocorticoid on septic rats [D]. Shijiazhuang:Hebei Medical University,2012.
[25] YIN S J. Chinese biology: plasma products from recovered patients were put into clinical practice, and signs and symptoms of the patients improved significantly [EB/OL]. [2020-02-14] http://www.xinhuanet. com/2020-02/14/c_1125573091. htm.